Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · CNS Pharmaceuticals, Inc. (CNSP)

CNS Pharmaceuticals raises approximately $22.5 million in private placement

Mixed Impact 3 of 5 financing Written later

CNS Pharmaceuticals agreed to sell 650,000 common shares and pre-funded warrants for 9,143,479 shares to institutional investors, with a closing expected May 5, 2026 and gross proceeds of approximately $22.5 million. The company plans to use the proceeds to acquire and advance new assets and for working capital, but the sale adds about 9.8 million shares that could dilute existing shareholders. The filing also reports a board resignation and the appointment of Michal Fisher as an independent director.

Key points

  • 650,000 common shares sold at $2.30 per share; pre-funded warrants for 9,143,479 shares sold at $2.299 each
  • Expected closing on May 5, 2026; placement agent fee of 7.0% of gross proceeds
  • Company to file a resale registration statement within 15 days of closing and agreed to a 120-day limit on most new equity sales
  • Jerzy (George) Gumulka resigned from the Board; Michal Fisher appointed as an independent director

The filing

CompanyCNS Pharmaceuticals, Inc. (CNSP)
Form8-K, current report
Filed with the SECMay 4, 2026, 7:05 AM ET
Accession number0001683168-26-003432

Items reported: 1.01 Material Definitive Agreement3.02 Unregistered Equity Sale5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 04, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.